SNHG8 promotes cell proliferation, migration, and invasion of nasopharyngeal carcinoma cells as an oncogene through miR-588/HMGA2 axis

High linc01116 expression may contribute to a poor prognosis in various cancers based on systematic reviews and meta-analyses

BACKGROUND

Long non-coding RNA 01116 (linc01116) has been shown to be dysregulated in many tumors, and is closely related to the prognosis. This meta-analysis aimed to examine the correlation between linc01116 expression and cancer prognosis.

METHODS

Six electronic databases were searched, and eligible studies were screened based on the inclusion and exclusion criteria. Data including hazard ratios (HRs) and 95% confidence intervals (CIs), TNM stage, distant metastasis (DM) status, lymph node metastasis (LNM) status, and tumor size were extracted from the included studies. HRs and odds ratios (ORs) with their corresponding 95% CIs were separately pooled to assess the relationship between linc01116 expression and cancer prognosis. Sensitivity analysis and Begg's test were performed to assess publication or other biases.

RESULTS

A total of 12 studies involving 809 patients were included in this meta-analysis. Analysis of pooled HRs with 95% CIs showed that high linc01116 expression was significantly correlated with poor overall survival (OS) (HR = 2.096; 95% CI: 1.555-2.638), progression-free survival (PFS) (HR, 1.9314; 95% CI: 1.020-3.657), disease-free survival (DFS) (HR = 2.067; 95% CI: 1.0889-3.9238), an advanced TNM stage (OR, 1.803; 95% CI: 1.270-2.562), and a poor histological grade (OR, 1.968; 95% CI: 1.288-3.007). However, no significant correlation was observed between linc01116 expression and LNM (OR, 1.198; 95% CI: 0.831-1.728), DM (OR, 1.114; 95% CI: 0.757-1.638), tumor size (OR, 1.336; 95% CI: 0.989-1.804), depth of invasion (OR, 1.375; 95% CI: 0.756-2.501), age (OR, 0.976; 95% CI: 0.742-1.283), or sex (OR, 0.810; 95% CI: 0.599-1.094). Sensitivity analysis indicated that the overall results of OS analysis were reliable and robust. In addition, Begg's test showed that none of the included studies had significant publication bias.

CONCLUSION

linc01116 is upregulated in most cancers, and this upregulation is associated with a poor prognosis. Therefore, linc01116 serves as a promising therapeutic target and prognostic biomarker for cancer.

lncRNAs are potential prognostic markers in patients with nasopharyngeal carcinoma in China: A systematic review and meta‑analysis

The present study aimed to investigate the association between the expression profiles of long non-coding RNAs (lncRNAs) and the clinical characteristics or prognosis of patients with nasopharyngeal carcinoma (NPC). The findings presented in the present review may provide novel strategies for the prevention and treatment of NPC. For the analyses, medical databases, including PubMed, Web of Science and Cochrane library were searched using specific search terms, search strategies and screening strategies. Endnote X9 document management software was then employed to extract documents from January, 2010 to May, 2023. Data were extracted following the prescribed standards. Review Manager 5.4 and STATA 12.0 data analysis software were used for data analysis. A total of 490 publications were analyzed for inclusion. In total, 29 publications, composed of 24 studies with upregulated lncRNAs and 5 studies with downregulated lncRNAs, were included in the final analysis. The analysis revealed that the upregulation of lncRNAs was significantly associated with T stage, N stage and clinical stage, as well as with the overall survival (OS) and disease-free survival (DFS) of patients with NPC (P<0.05). However, there was no significant association between the upregulated lncRNAs and sex, M stage or relapse-free survival (RFS) (P>0.05). On the other hand, the suppression of lncRNA expression was significantly associated with N stage, M stage, clinical stage and the OS of patients with NPC (P<0.05), but not with T stage and RFS (P>0.05). Taken together, the present review demonstrates that the up- and downregulation of different lncRNAs was associated with an advanced clinical stage and a shorter OS of patients with NPC. Therefore, lncRNAs may serve as potential prognostic factors in NPC.

Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma

Background: Clear cell renal cell carcinoma (ccRCC) accounts for 80% of all kidney cancers and has a poor prognosis. Recent studies have shown that copper-dependent, regulated cell death differs from previously known death mechanisms (apoptosis, ferroptosis, and necroptosis) and is dependent on mitochondrial respiration (Tsvetkov et al., Science, 2022, 375 (6586), 1254–1261). Studies also suggested that targeting cuproptosis may be a novel therapeutic strategy for cancer therapy. In ccRCC, both cuproptosis and lncRNA were critical, but the mechanisms were not fully understood. The aim of our study was to construct a prognostic profile based on cuproptosis-associated lncRNAs to predict the prognosis of ccRCC and to study the immune profile of clear cell renal cell carcinoma (ccRCC).

Methods: We downloaded the transcriptional profile and clinical information of ccRCC from The Cancer Genome Atlas (TCGA). Co-expression network analysis, Cox regression method, and least absolute shrinkage and selection operator (LASSO) method were used to identify cuproptosis-associated lncRNAs and to construct a risk prognostic model. In addition, the predictive performance of the model was validated and recognized by an integrated approach. We then also constructed a nomogram to predict the prognosis of ccRCC patients. Differences in biological function were investigated by GO, KEGG, and immunoassay. Immunotherapy response was measured using tumor mutational burden (TMB) and tumor immune dysfunction and rejection (TIDE) scores.

Results: We constructed a panel of 10 cuproptosis-associated lncRNAs (HHLA3, H1-10-AS1, PICSAR, LINC02027, SNHG15, SNHG8, LINC00471, EIF1B-AS1, LINC02154, and MINCR) to construct a prognostic prediction model. The Kaplan–Meier and ROC curves showed that the feature had acceptable predictive validity in the TCGA training, test, and complete groups. The cuproptosis-associated lncRNA model had higher diagnostic efficiency compared to other clinical features. The analysis of Immune cell infiltration and ssGSEA further confirmed that predictive features were significantly associated with the immune status of ccRCC patients. Notably, the superimposed effect of patients in the high-risk group and high TMB resulted in shorter survival. In addition, the higher TIDE scores in the high-risk group suggested a poorer outcome for immune checkpoint blockade response in these patients.

Conclusion: The ten cuproptosis-related risk profiles for lncRNA may help assess the prognosis and molecular profile of ccRCC patients and improve treatment options, which can be further applied in the clinic.